Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety Oversight Board Will Require Two-Thirds Majority For Recommendations

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Drug Safety Oversight Board will need a two-thirds majority of a quorum to make recommendations, a Center for Drug Evaluation & Research Manual of Policies & Procedures states

You may also be interested in...



FDA Has Its Own Peer Review Process, Gottlieb Says

FDA Deputy Commissioner Gottlieb defends agency decision-making practices in face of criticism from medical journals.

FDA Has Its Own Peer Review Process, Gottlieb Says

FDA Deputy Commissioner Gottlieb defends agency decision-making practices in face of criticism from medical journals.

Drug Safety Oversight Board Proceedings Should Be More Open, Rep. DeLauro Says

FDA Commissioner Crawford defends the board as an "instrument of openness" in response to complaints that the panel's closed proceedings will fail to provide greater transparency.

Related Content

Topics

UsernamePublicRestriction

Register

PS062325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel